����������

Medicare will cover new Alzheimer’s drugs that receive traditional approval from the Food and Drug Administration when a beneficiary is diagnosed with mild cognitive impairment or Alzheimer’s disease dementia and has a physician participating in a registry with an appropriate clinical team and follow-up care, the Centers for Medicare & Medicaid Services June 22. CMS called the approach consistent with its 2022 national coverage for the first monoclonal antibodies targeting amyloid to treat Alzheimer’s.